Synopsis
Synopsis
0
CEP/COS
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)-3-pyridinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid
2. Ozanex
3. Xepi
1. 245765-41-7
2. Xepi
3. T-3912
4. T 3912
5. 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxoquinoline-3-carboxylic Acid
6. Gf-001001-00
7. V0lh498rfo
8. 1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)pyridin-3-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
9. Ozenoxacin Cream
10. Ozenoxacin [inn]
11. Ozenoxacin [inn:jan]
12. Unii-v0lh498rfo
13. Ozadub
14. Xepi (tn)
15. Ozenoxacin [mi]
16. Ozenoxacin; T-3912
17. Ozenoxacin [jan]
18. Ozenoxacin [usan]
19. Ozenoxacin [who-dd]
20. Ozenoxacin (jan/usan/inn)
21. Schembl1711829
22. Chembl3990047
23. Ozenoxacin [orange Book]
24. Gtpl10841
25. Dtxsid00947446
26. Chebi:136050
27. Bcp16621
28. Ex-a2693
29. Vja76541
30. Who 8788
31. Zinc1483896
32. S6582
33. Akos032947315
34. At18754
35. Db12924
36. Sb16801
37. Ncgc00532517-01
38. Bs-16742
39. Da-31712
40. Hy-14957
41. Ozenoxacin 100 Microg/ml In Acetonitrile
42. Cs-0003657
43. Ft-0701296
44. D09544
45. Q17125399
46. Gf-001001-00; M-5120; T-3912; Gf-00100100;t3912;t 3912
47. 1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)-3-pyridinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid
48. 3-quinolinecarboxylic Acid, 1-cyclopropyl-1,4-dihydro-8-methyl-7-(5-methyl-6-(methylamino)-3-pyridinyl)-4-oxo-
Molecular Weight | 363.4 g/mol |
---|---|
Molecular Formula | C21H21N3O3 |
XLogP3 | 4.1 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 4 |
Exact Mass | 363.15829154 g/mol |
Monoisotopic Mass | 363.15829154 g/mol |
Topological Polar Surface Area | 82.5 Ų |
Heavy Atom Count | 27 |
Formal Charge | 0 |
Complexity | 645 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Ozenoxacin cream is indicated for the topical treatment of impetigo caused by *Staphylococcus aureus* or *Streptococcus pyogenes* in patients aged 2 months of age and older.
FDA Label
Treatment of impetigo
Although the exposure response relationship for ozenoxacin after it has been applied topically has not yet been studied, a formal relationship is unlikely because systemic exposure of ozenoxacin following its topical application has been measured to be negligible.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Topoisomerase Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASES. (See all compounds classified as Topoisomerase Inhibitors.)
D - Dermatologicals
D06 - Antibiotics and chemotherapeutics for dermatological use
D06A - Antibiotics for topical use
D06AX - Other antibiotics for topical use
D06AX14 - Ozenoxacin
Absorption
Four studies were performed in which varying strengths of ozenoxacin cream, up to 2% (twice the concentration of the marketed formulation), were administered to 110 patients. Three of the studies examined systemic absorption in healthy subjects and in subjects having impetigo. The studies were performed with either single or repeated application of up to 1 g ozenoxacin cream to intact or abraded skin (up to 200 cm squared surface area). No systemic absorption was seen in 84 of 86 subjects, and negligible systemic absorption was seen at the level of detection (0.489 ng/mL) in 2 subjects.
Route of Elimination
Studies regarding elimination and excretion have not yet been investigated in humans due to the negligible systemic absorption observed in clinical studies.
Volume of Distribution
Ozenoxacin undergoes negligible systemic absorption after its topical administration. Subsequently, since negligible systemic absorption of ozenoxacin was observed in clinical studies, tissue distribution has not been investigated in humans either.
Clearance
Ozenoxacin undergoes negligible systemic absorption after its topical administration.
Studies have demonstrated that ozenoxacin is not metabolized in the presence of fresh human skin discs and is minimally metabolized in human hepatocytes.
Ozenoxacin is a quinolone antibiotic drug. And, like most quinolones, ozenoxacin predominately executes its mechanism of action by entering into bacterial cells and acting to inhibit the bacterial DNA replication enzymes DNA gyrase A and topoisomerase IV. As DNA gyrase A and topoisomerase IV are essential to bacterial DNA replication activities including supercoiling, supercoil relaxation, chromosomal condensation, chromosomal decatenation and more, their inhibition is the principal action of ozenoxacin's mechanism and it has been demonstrated to be bactericidal against *S. aureus* and *S. pyogenes* organisms.
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
51
PharmaCompass offers a list of Ozenoxacin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ozenoxacin manufacturer or Ozenoxacin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ozenoxacin manufacturer or Ozenoxacin supplier.
PharmaCompass also assists you with knowing the Ozenoxacin API Price utilized in the formulation of products. Ozenoxacin API Price is not always fixed or binding as the Ozenoxacin Price is obtained through a variety of data sources. The Ozenoxacin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 245765-41-7 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 245765-41-7, including repackagers and relabelers. The FDA regulates 245765-41-7 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 245765-41-7 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of 245765-41-7 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A 245765-41-7 supplier is an individual or a company that provides 245765-41-7 active pharmaceutical ingredient (API) or 245765-41-7 finished formulations upon request. The 245765-41-7 suppliers may include 245765-41-7 API manufacturers, exporters, distributors and traders.
click here to find a list of 245765-41-7 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A 245765-41-7 DMF (Drug Master File) is a document detailing the whole manufacturing process of 245765-41-7 active pharmaceutical ingredient (API) in detail. Different forms of 245765-41-7 DMFs exist exist since differing nations have different regulations, such as 245765-41-7 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A 245765-41-7 DMF submitted to regulatory agencies in the US is known as a USDMF. 245765-41-7 USDMF includes data on 245765-41-7's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 245765-41-7 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of 245765-41-7 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The 245765-41-7 Drug Master File in Japan (245765-41-7 JDMF) empowers 245765-41-7 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the 245765-41-7 JDMF during the approval evaluation for pharmaceutical products. At the time of 245765-41-7 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of 245765-41-7 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a 245765-41-7 Drug Master File in Korea (245765-41-7 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of 245765-41-7. The MFDS reviews the 245765-41-7 KDMF as part of the drug registration process and uses the information provided in the 245765-41-7 KDMF to evaluate the safety and efficacy of the drug.
After submitting a 245765-41-7 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their 245765-41-7 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of 245765-41-7 suppliers with KDMF on PharmaCompass.
A 245765-41-7 written confirmation (245765-41-7 WC) is an official document issued by a regulatory agency to a 245765-41-7 manufacturer, verifying that the manufacturing facility of a 245765-41-7 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting 245765-41-7 APIs or 245765-41-7 finished pharmaceutical products to another nation, regulatory agencies frequently require a 245765-41-7 WC (written confirmation) as part of the regulatory process.
click here to find a list of 245765-41-7 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 245765-41-7 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for 245765-41-7 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture 245765-41-7 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain 245765-41-7 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 245765-41-7 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of 245765-41-7 suppliers with NDC on PharmaCompass.
245765-41-7 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 245765-41-7 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 245765-41-7 GMP manufacturer or 245765-41-7 GMP API supplier for your needs.
A 245765-41-7 CoA (Certificate of Analysis) is a formal document that attests to 245765-41-7's compliance with 245765-41-7 specifications and serves as a tool for batch-level quality control.
245765-41-7 CoA mostly includes findings from lab analyses of a specific batch. For each 245765-41-7 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
245765-41-7 may be tested according to a variety of international standards, such as European Pharmacopoeia (245765-41-7 EP), 245765-41-7 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (245765-41-7 USP).